Objective-Dihydrofolate reductase (DHFR) is a key protein involved in tetrahydrobiopterin (BH 4 ) regeneration from 7,8-dihydrobiopterin (BH 2 ). Dysfunctional DHFR may induce endothelial nitric oxide (NO) synthase (eNOS) uncoupling resulting in enzyme production of superoxide anions instead of NO. The mechanism by which DHFR is regulated is unknown. Here, we investigate whether eNOS-derived NO maintains DHFR stability. Approach and Results-DHFR activity, BH 4 content, eNOS activity, and S-nitrosylation were assessed in human umbilical vein endothelial cells and in aortas isolated from wild-type and eNOS knockout mice. In human umbilical vein endothelial cells, depletion of intracellular NO by transfection with eNOS-specific siRNA or by the NO scavenger 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide (PTIO)-both of which had no effect on DHFR mRNA levels-markedly reduced DHFR protein levels in parallel with increased DHFR polyubiquitination. Supplementation of S-nitrosol-glutathione (GSNO), a NO donor, or MG132, a potent inhibitor of the 26S proteasome, prevented eNOS silencing and PTIO-induced DHFR reduction in human umbilical vein endothelial cells. PTIO suppressed S-nitrosylation of DHFR, whereas GSNO promoted DHFR S-nitrosylation. Mutational analysis confirmed that cysteine 7 of DHFR was S-nitrosylated. Cysteine 7 S-nitrosylation stabilized DHFR from ubiquitination and degradation. Experiments performed in aortas confirmed that PTIO or eNOS deficiency reduces endothelial DHFR, which can be abolished by MG132 supplementation. Conclusions-We conclude that S-nitrosylation of DHFR at cysteine 7 by eNOS-derived NO is crucial for DHFR stability.
N itric oxide (NO), an essential molecule in maintaining cardiovascular health, is derived from l-arginine in an oxidizing reaction catalyzed by NO synthase (NOS). Three distinct isoforms of NOS have been identified in mammalian cells: neuronal NOS, inducible NOS, and endothelial NOS (eNOS). The eNOS isoform is a major source of NO produced by endothelial cells, 1 and an overwhelming amount of evidence indicates that dysfunctional eNOS is associated with the pathogenesis of various vascular diseases, including atherosclerosis and hypertension. 2, 3 Under such conditions, endothelial NO bioactivity is diminished and oxidative stress increases, resulting in endothelial dysfunction. 4, 5 
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The enzymatic function of eNOS is tightly regulated by various factors. One cofactor, tetrahydrobiopterin (BH 4 ), helps to maintain enzyme coupling. 1 When oxidized or reacted with peroxynitrite, BH 4 forms 7,8-dihydrobiopterin (BH 2 ) and trihydrobiopterin radical accordingly, which inactivates NOS function by competing with BH 4 for eNOS binding; this ultimately causes eNOS uncoupling. [6] [7] [8] Under such condition, the enzyme is converted from an NO-producing enzyme to a molecule that generates superoxide anions. 9 Two key enzymes regulate the concentration of BH 4 . GTP cyclohydrolase I (GTPCH) controls de novo biosynthesis from GTP, 10 and dihydrofolate reductase (DHFR) is the key enzyme responsible for salvation of BH 4 from BH 2 at the expense of nicotinamide adenine dinucleotide phosphate oxidase. 11 Recent studies indicate that angiotensin II downregulates DHFR expression, decreases BH 4 levels, and increases eNOS uncoupling in endothelial cells through oxidative stress. 12 In addition, DHFR inhibition or knockdown diminishes the BH 4 :BH 2 ratio and exacerbates eNOS uncoupling. 11, 13 In fact, BH 4 -deficient (hph-1) mice treated with methotrexate to inhibit BH 4 recycling by DHFR displayed strikingly elevated BH 2 levels and decreased BH4:BH2 ratio in the aortas. 7 Despite results from previous studies suggesting that GTPCH and DHFR mediate eNOS function, it is unknown whether eNOS feedback regulates these 2 enzymes.
In addition to vasodilation, NO is also involved in various signaling pathways. In these pathways, NO targets specific cysteine residues, resulting in covalent incorporation of NO into thiol groups to form S-nitrosothiol, termed S-nitrosylation. 14 We previously reported that NO can activate GTPCH activity through S-nitrosylation in endothelial cells. 15 However, it is unknown whether eNOS-derived NO has the potential to S-nitrosylate DHFR to regulate its function. DHFR expression is regulated by various mechanisms, including transcription and degradation, which are mediated via the ubiquitin-proteasome pathway. 16 Previous reports suggest that certain post-translational modifications may regulate protein ubiquitination and function. 14, 17 S-nitrosylation in particular may inhibit degradation of certain proteins, such as Bcl-2 (B-cell lymphoma 2) and TRIM72 (tripartite motifcontaining protein 72) and promote degradation of other proteins, such as Parkin. [18] [19] [20] In this study, we hypothesized that NO generated by eNOS stabilizes DHFR via S-nitrosylation, which regenerates BH 4 to maintain the eNOS-coupling status.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results eNOS Silencing Reduces DHFR Protein Expression in Human Umbilical Vein Endothelial Cells
Confluent human umbilical vein endothelial cells (HUVECs) express high levels of eNOS, GTPCH, and DHFR ( Figure 1A ).
To determine whether eNOS expression alters GTPCH and DHFR levels, confluent HUVECs were transfected with scramble siRNA or eNOS-specific siRNA. eNOS-specific siRNA markedly reduced eNOS levels compared with those transfected with control siRNA, 48 hours after transfection ( Figure 1A) , indicating that eNOS-specific siRNA targets only eNOS. Neither control siRNA nor eNOS-specific siRNA affected the levels of GTPCH ( Figure 1A ). Interestingly, DHFR protein expression in eNOS-silenced HUVECs was markedly lower than that in HUVECs transfected with control siRNA ( Figure 1A) ; however, eNOS silencing did not significantly alter DHFR mRNA levels ( Figure 1B ).
We also tested the effect of eNOS inhibition by N-nitro-L-arginine methyl ester (L-NAME) on DHFR and GTPCH expression. Similar to the results of eNOS siRNA silencing, L-NAME reduced DHFR expression from the 1 mmol/L to 2 mmol/L but had no effect on GTPCH expression ( Figure I in the online-only Data Supplement).
eNOS-Derived NO Prevents DHFR Reduction in HUVECs
The major function of eNOS is to generate NO. Next, we investigated whether reduced NO release in eNOS-silenced HUVECs results in reduced expression of DHFR. To this end, HUVECs were exposed to 2-(4-carboxyphenyl)-4,4,5,5tetramethylimidazoline-1-oxyl-3-oxide (PTIO), a known NO scavenger. 21 As shown in Figure 1C , treatment of HUVECs with PTIO for 24 hours dose dependently reduced DHFR protein levels from 150 to 300 μmol/L. Exposure of HUVECs to PTIO (150 μmol/L) for 6 and 12 hours had marginal effects on DHFR expression. Prolonged exposure of HUVECs to PTIO for 24 to 48 hours significantly reduced DHFR ( Figure 1C ). PTIO did not alter DHFR mRNA levels ( Figure 1D ). In addition, PTIO incubation did not alter GTPCH expression at a maximum dose of 300 μmol/L for 48 hours ( Figure 1C ).
Because both eNOS silencing and NO scavenging via PTIO lowered DHFR levels in HUVECs, we reasoned that exposure of HUVECs to a NO donor would ablate DHFR reduction in eNOS-silenced HUVECs. As depicted in Figure 1E and 1F, exposure of HUVECs to S-nitroso-l-glutathione (GSNO), a NO donor, reversed DHFR reduction induced by eNOS siRNA transfection or PTIO incubation. These results indicate that eNOS-derived NO is essential for maintaining DHFR expression without affecting mRNA levels.
Peroxynitrite Does Not Affect DHFR Expression in HUVECs
Superoxide anions could deplete NO to generate peroxynitrite (ONOO − ), which is crucial in the pathogenesis in hypertension and endothelial dysfunction. We further tested whether ONOO − may affect DHFR in HUVECs. As shown in Figure II in the online-only Data Supplement, addition of ONOO − ranging from 50 to 500 μmol/L induced protein tyrosine nitration in a dose-dependent manner. GTPCH expression decreased as the increased dose of ONOO − , which is in consistent with our previous report. 10 However, DHFR expression remained unchanged, indicating that ONOO − has no effect on DHFR expression.
NO Stabilizes the DHFR Protein in HUVECs
Because NO depletion in HUVECs only suppressed DHFR protein expression without altering mRNA levels, we investigated whether NO affects the stability of the DHFR protein. To this end, protein stability (half-life) was measured in the presence of cycloheximide, an inhibitor of de novo protein synthesis. As depicted in Figure 2A , in the absence of cycloheximide, the DHFR protein decreased by ≈50% after 4 hours and continued to decline after 8 hours. As depicted in Figure 2A , GSNO treatment significantly inhibited DHFR reduction in the presence of cycloheximide, and the DHFR half-life was increased to 7.86 hours. 
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NO Depletion Promotes DHFR Degradation via the Ubiquitin-Proteasome System in HUVECs
The ubiquitin-proteasome system is important for intracellular protein degradation. 22 It has been reported that DHFR can be ubiquitinated and degraded by the proteasome. 23 To examine whether NO depletion caused by eNOS silencing or PTIO leads to DHFR reduction via ubiquitin-proteasome degradation, eNOS siRNA-treated or PTIO-treated HUVECs were coincubated with MG132, a potent 26S proteasome inhibitor. As depicted in Figure 2B and 2C, MG132 ablated DHFR reduction caused by eNOS silencing or PTIO. In parallel, PTIO increased the detection of ubiquitinated DHFR ( Figure 2D ). GSNO pretreatment abolished PTIO-enhanced DHFR ubiquitination. These data suggest that NO via the ubiquitin-proteasome system promotes DHFR ubiquitination and 26S proteasome-mediated degradation.
NO Depletion Reduces DHFR Activity and BH 4 Levels in HUVECs
DHFR is the key enzyme responsible for salvation formation of BH 4 . 11 Therefore, we determined whether NO depletion altered the function of DHFR in HUVECs. In parallel with decreased protein levels, DHFR activity and intracellular BH 4 were markedly suppressed by eNOS silencing. These effects were restored by MG132 or GSNO treatment ( Figure 
NO S-Nitrosylates DHFR at Cysteine 7 in HUVECs
Next, we sought to explore how NO regulates DHFR. Since NO leads to S-nitrosylation of certain proteins, 18, 20 we tested whether NO could also S-nitrosylate DHFR. As shown in Figure 3A , GSNO markedly increased DHFR S-nitrosylation, whereas PTIO significantly reduced S-nitrosylation. There is only 1 cysteine residue (C7) in human DHFR, which is conserved among species ( Figure 3B ), suggesting that it is the residue to be S-nitrosylated. To confirm cysteine 7 is the target for S-nitrosylation, we generated a DHFR mutant, in which cysteine 7 of DHFR was replaced with serine (C7S). Both wild-type (WT) DHFR and the C7S mutant were transfected into HUVECs. After transfection, the cells were treated with GSNO for 6 hours. As expected, the C7S mutation in DHFR blocked basal-and GSNO-induced S-nitrosylation of DHFR ( Figure 3C ).
C7 S-Nitrosylation Stabilizes DHFR in HUVECs
S-nitrosylation of certain proteins may influence their stability. 19, 24 We explored whether C7 S-nitrosylation of DHFR affects its stability. WT or C7S mutant DHFR plasmids were transfected into HUVECs. The C7S mutation of DHFR shortened the half-life of the protein compared with the WT (Figure 4A) . GSNO significantly increased the half-life of WT DHFR, but the C7S mutation blocked this effect in HUVECs ( Figure 4A ). These data suggest that S-nitrosylation of DHFR at C7 stabilizes the protein.
S-Nitrosylation of DHFR Prevents It From Ubiquitination and Degradation
Because the ubiquitin-proteasome system is involved in NO depletion-induced DHFR degradation, we next determined whether S-nitrosylation of DHFR initiates ubiquitination and degradation of DHFR. As expected, in parallel with increased S-nitrosylation ( Figure 4B ), GSNO supplementation markedly lowered PTIOenhanced DHFR ubiquitination in HUVECs ( Figure 4C ).
NO directly regulates proteasome activity. 25 To exclude the possibility that NO-suppressed DHFR degradation occurs via suppressed proteasome activity, HUVECs were treated with dithiothreitol, a known inhibitor of S-nitrosylation, 26 in addition to GSNO and PTIO. As shown in Figure 4E , PTIO increased proteasome activity, which was reversed by addition of GSNO. Although supplementation with dithiothreitol blocked the effects of GSNO on DHFR ubiquitination and degradation ( Figure 4C and 4D) , it had no effect on proteasome activity ( Figure 4E ).
S-Nitrosylation of DHFR Does Not Affect Its Activity In Vitro
Next, we tested whether S-nitrosylation of DHFR at C7 affects its activity. Recombinant His-tagged WT and C7S DHFR proteins were successfully generated and incubated with GSNO to induce S-nitrosylation. As expected, GSNO increased S-nitrosylation of WT DHFR but had no effect on S-nitrosylation in C7S DHFR mutation in vitro ( Figure IVA in the online-only Data Supplement). DHFR activity was further assessed. As shown in Figure IVB in the online-only Data Supplement, the in vitro assay showed no difference between the WT and C7S DHFR activities, and GSNO incubation did not affect their activities.
NO Depletion Suppresses Aortic Endothelial DHFR Expression and BH 4 Content via Proteasomal Degradation Ex Vivo
The effects of NO and proteasome degradation on endothelial DHFR in aortas were further tested in ex vivo system. Aortic segments isolated from 8-week-old mice were incubated with PTIO for 24 hours. As shown in Figure 5A to 5C, PTIO Figure 5A-C) . As expected, the endothelial GTPCH expression was not altered by PTIO incubation (Figure 5D and 5E).
We next assayed the BH 4 and total biopterin levels in ex vivo cultured aortas. Similar to the effect on DHFR protein expression, PTIO significantly reduced BH 4 levels, which was restored by MG132 ( Figure 5F ).
eNOS Deficiency Reduces Endothelial DHFR Expression and BH 4 Content via Proteasomal Degradation In Vivo
Because the above data show that NO prevents endothelial DHFR degradation both in HUVECs and ex vivo aortas, we reasoned that eNOS deficiency may lead to reduced endothelial DHFR expression and BH 4 content. Indeed, immunofluorescence staining revealed reduced endothelial DHFR expression in aorta from eNOS −/− mice compared with WT mice (Figure 6A and 6B) . In contrast, the expression of GTPCH was comparable between WT and eNOS −/− mice ( Figure 6C and 6D) .
Next, we determined whether proteasome inhibition increased the levels of DHFR in the aortas of eNOS −/− . To test this, both WT and eNOS −/− mice received intraperitoneal injection of MG132. As depicted in Figure 6A and 6B, MG132 increased the levels of DHFR in endothelial cells.
Finally, we detected BH 4 and total biopterin levels in aortas. As expected, aortas from eNOS −/− mice showed reduced levels of BH 4 compared with WT mice, which was reversed by MG132 intraperitoneal injection ( Figure 6E ). These data further support that NO prevents endothelial DHFR degradation through the proteasome system both in vitro and in vivo.
Discussion
In this study, we demonstrate for the first time that NO derived from eNOS regulates DHFR expression and function. The major finding in this study is that NO generated by eNOS promotes DHFR S-nitrosylation at C7. Furthermore, we found that S-nitrosylation of DHFR inhibits DHFR ubiquitination and proteasome degradation. Stimuli that deplete intracellular NO lead to the reduction of DHFR S-nitrosylation and result in its degradation through the ubiquitin-proteasome system. The NO donor GSNO efficiently reversed the effects. Consistently, DHFR is markedly lower in the endothelium from eNOS −/− mice when compared with those in WT mice. Finally, proteasome inhibition with MG132 increased DHFR expression in the endothelium of eNOS −/− mice. Taken together, we conclude that NO derived from eNOS is a key factor in maintaining DHFR stability, BH4 contents, and eNOS uncoupling.
It has been well documented that DHFR and GTPCH regulate eNOS coupling via maintaining BH 4 content. 9 We show here that eNOS deficiency reduces DHFR but not GTPCH expression both in vivo and in vitro. The major function of eNOS is to generate NO, and studies reveal that NO participates in various signaling pathways and exerts multibiological functions. 27 Our data show that NO also regulates DHFR expression. We found that depletion of NO by eNOS deficiency or PTIO reduced DHFR protein levels, paralleled by reduced DHFR activity and intracellular BH 4 content but not by a reduction in mRNA levels. This suggests post-transcriptional regulation of DHFR is responsible for the reduction. Indeed, we found PTIO increased DHFR ubiquitination. The ability of the 26S proteasome inhibitor MG132 to suppress DHFR reduction caused by NO depletion strongly supports the role of the proteasome pathway in DHFR degradation.
NO reacts with cysteine residues to form S-nitrosothiol, and the S-nitrosylated proteins have been increasingly recognized as important determinants of many biochemical processes. 28 Our laboratory previously reported that NO is able to S-nitrosylate GTPCH, the key enzyme in de novo BH 4 synthesis pathway. 15 However, whether NO can also S-nitrosylate DHFR and how it affects the protein remains unknown.
Here, we found that NO donor GSNO increased DHFR S-nitrosylation, whereas NO scavenger PTIO decreased its S-nitrosylation. We further identified that C7 of DHFR is the site of S-nitrosylation, which leads to increased stability. Addition of the NO donor GSNO increased DHFR C7 S-nitrosylation and suppressed DHFR reduction in the presence of cycloheximide. However, mutation of this cysteine residue blocked the effect. These data support the role of C7 S-nitrosylation on DHFR degradation process.
S-nitrosylation of proteins is reported to regulate their ubiquitination and stability. 26, 29 Our results show that S-nitrosylation of DHFR prevents it from ubiquitination, thereby reducing degradation. The mechanism by which S-nitrosylation prevents DHFR ubiquitination is unclear but may attribute to the conformational change of the protein, which prevents recognition and subsequent attachment of ubiquitin by the enzyme ubiquitin ligases.
This study demonstrates that NO could stabilize DHFR via S-nitrosylation and therefore help to maintain eNOS-coupling status. However, it is also reported that overproduction of NO could also S-nitrosylate eNOS and suppress its function. 30 These data suggest that 2 mechanisms of NO S-nitrosylation may work together to maintain eNOS in normal function.
This study used PTIO as an NO scavenger. However, it is reported that PTIO reacts with NO and generates NO 2 radicals, 31 which could then lead to tyrosine nitration of proteins. Despite this side effect of PTIO, our results already showed that tyrosine nitration caused by ONOO − had no effect on DHFR, which indicates that the effect of PTIO on DHFR was not because of tyrosine nitration. BH 4 plays an important role in eNOS coupling, which is crucial in maintaining endothelial function. 32 In fact, supplementation of BH 4 would seem to be a promising strategy for improving the vascular status in such diseases. Unfortunately, application of this strategy to improve endothelial function in vascular disease has resulted in less than satisfactory results. 33, 34 Studies show that treatment of human endothelial cells with BH 4 may only transiently increased intracellular BH 4 , which is quickly oxidized, causing the accumulation of BH 2 . This form is inactive as a NOS cofactor and may compete with BH 4 for NOS binding and increase eNOS uncoupling. 13, 34 This may limit the benefits of BH 4 therapies but suggest that DHFR controlling the salvage pathway of BH 4 synthesis might be more crucial in balancing intracellular BH 4 :BH 2 ratio than we originally thought.
In summary, this study provides evidence to suggest that eNOS-derived NO is critical for maintaining DHFR expression in endothelial cells. Stimuli causing NO depletion induces DHFR downregulation through ubiquitin-proteasome-dependent degradation. This is mediated by reduced S-nitrosylation DHFR at C7, which leads to its instability. This signaling cascade may represent a common mechanism that eNOS regulates its homeostasis by maintaining DHFR S-nitrosylation.
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